ACTRN12622001534774已完成1 期
Phase 1 dose-escalation study assessing the safety and pharmacokinetics of PTC607 in healthy volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •1. Males and females aged 18 to 65 years inclusive at Screening
- •2. Participants able to provide informed consent
- •3. Body mass index of greater than or equal to 18.5 and less than or equal to 30.0 kg/m2 with a body weight of greater than or equal to 50.0 kg for male
- •participants and a body weight of greater than or equal to 45.0 kg for female participants at Screening
- •4. Generally healthy as determined by the investigator based on medical evaluation, including medical history, physical examination, laboratory test results, ECG, and vital signs.
- •5. Male participants must be willing to use 2 acceptable contraceptive methods for the duration of the study and for a minimum of 6 months after the last dose, and female participants of childbearing potential must be willing to use 2 acceptable contraceptive methods for the duration of the study and for a minimum of 30 days after the last dose.
- •6. All female participants of childbearing potential must have a negative serum pregnancy
- •test result at Screening and a negative urine pregnancy test on Day -1.
- •7. Male participants must agree to not donate sperm for the duration of the study and for at
- •least 6 months after the last dose.
排除标准
- •1. Participants that participated in any drug or device clinical investigation within 60 days
- •prior to Screening or who anticipate participating in any drug or device clinical
- •investigation within the duration of this study.
- •2. Prior or ongoing medical condition (eg, concomitant illness, psychiatric condition),
- •medical history, and/or physical findings that, in the investigator’s opinion, could
- •adversely affect the safety of the participant or could impair the assessment of study
- •3. An abnormal general neurological examination.
- •4. Presence of any clinically significant abnormality during Screening.
- •5. Any psychological or emotional problems, any disorders, or resultant therapy that is
- •likely to invalidate informed consent or limit the ability of the participant to comply with
- •the protocol requirements.
- •6. A positive hepatitis B surface antigen, positive hepatitis C antibody, or HIV antibody
- •result at Screening.
- •7. Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding
- •volume drawn at Screening or menses) of 50 to 499 mL within 30 days or more than
- •499 mL within 56 days prior to dosing.
- •8. Excessive alcohol consumption (regular alcohol intake greater than or equal to 21 units per week for male
- •participants and greater than or equal to 14 units per week for female participants) within 6 months prior to
- •Screening. One unit (8 g) is equivalent to a half pint (280 mL) of beer, 1 measure
- •(25 mL) of spirits, or 1 small glass (125 mL) of wine.
- •9. The participant is a smoker or uses other nicotine-containing products. Ex-smokers must
- •have ceased smoking >3 months prior to Screening. Smokers who consume <4 tobacco
- •products per week are allowed.
- •10. The participant has consumed grapefruit (or its juice), star fruit, pomegranate, pomelo,
- •tangelo, or Seville orange-containing products in the 1 week before Screening.
- •11. A positive urine drug screen, cotinine screen, or alcohol breath test at Screening or on
- •Day -1 of each treatment period.
- •12. Females who are pregnant or nursing.
- •13. Participant has previously received PTC607.
研究者
相似试验
尚未招募
1 期
First in human study of multiple doses of a novel drug PTC607 to assess its safety and tolerability in healthy participantsHuntington's DiseaseNeurological - Neurodegenerative diseasesHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12623001325695CTI Clinical Trial and Consulting Services Australia Pty Ltd24
已完成
不适用
A Phase I, Dose Escalation Study on the Safety, Pharmacokinetics and Pharmacodynamics of Coagulation Factor VIIa (Recombinant) and its Comparability to NovoSeven® in Healthy Male Volunteers Pre-Treated with Fondaparinuxhaemophilia10064477NL-OMON34613Centre for Human Drug Research36
已完成
1 期
Clinical trial to evaluate safety, tolerability and pharmacokinetic of herbal (ICB-014-A002) capsule in healthy adult volunteers.CTRI/2018/01/011259Indian Institute of Integrative Medicine Council of Scientific Industrial Research38
已完成
不适用
Single dose escalation study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BAY 2413555 after oral dosing in healthy male participants in a randomized, single-blind, placebo-controlled, group-comparison desigHeart FailureNL-OMON54965Bayer AG90
未知
1 期
Phase11 study of OPB-51602 in patients with hematologic malignanciesmultiple myeloma [MM], non-Hodgkin lymphoma [NHL], acute myeloid leukemia [AML], acute lymphoid leukemia [ALL], chronic myeloid leukemia [CML]JPRN-jRCT2080221439Otsuka Pharmaceutical Co., Ltd.